HUMA at a glance
Humacyte, Inc. (HUMA, SEC CIK 1818382) filed its latest 10-K annual report on March 27, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on September 28, 2026 and Form 4 insider filings as recently as September 15, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Humacyte, Inc. (HUMA) reported revenue of $2.0 million and a net loss of $40.8 million. Diluted EPS was -$0.26.
- As of June 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Humacyte, Inc. (HUMA) shares worth $19.3 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Jones Keith Anthony on September 14, 2026 of 10,000 shares at $0.56 per share.
- In the last 90 days, HUMA insiders reported 3 open-market purchases ($30K) and 0 open-market sales ($0) on Form 4, a net purchase of $30K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.0M
- 10-K XBRL
- Insiders · 90 days
- 3 buys · 0 sells
- Net +$30K
- 13F holders
- 24 funds
- $19.3M · −2 vs prior quarter
- Latest 8-K
- Sep 28, 2026
- Item 7.01 · Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $0.4M, up 35% YoY from $0.3M; Symvess product revenue $0.4M vs $0.1M
- Operating loss $27.0M vs $29.7M; operating margin -6,649.3% vs -9,875.4% YoY
- Worst cost impact: cost of goods sold $1.2M vs $0.2M, including $0.7M inventory reserve
- Cash $79.9M plus restricted cash $0.4M; operating cash outflow $47.2M for six months
- $53.8M net proceeds from equity offering; workforce reductions expected to save $14.3M
Risk Factors
- Workforce reduction: May 2026 plan eliminated approximately 45 employees and deferred planned hires
- Nasdaq compliance: $1.00 minimum bid-price deficiency triggered a 180-day cure period through January 27, 2027
- Delisting risk: Failure to regain compliance could impair liquidity and access to additional capital
- Cost-saving execution: Severance costs and employee attrition could reduce cash flows and disrupt productivity
- Equity dilution: Mayo Clinic received warrants for 240,000 shares at a $1.11 exercise price
AI summary of the HUMA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Board appointments of Mr. Coward and Mr. Kuznik, signaling changes in Humacyte’s governance and strategic oversight
- Press release furnished as Exhibit 99.1, containing appointment details relevant to shareholder assessment
Item EX-99.1: Item EX-99.1
- Board additions target commercialization and global operations as Humacyte expands Symvess launch and prepares dialysis-access ATEV launch
- Scott Coward adds public-company governance, M&A integration, legal, and compliance expertise through Audit Committee appointment
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board expansion adds Scott Coward as Class I director through 2028 and Paul Kuznik as Class II director through 2029
- Coward joins Audit Committee, adding public-company governance, legal, M&A and integration expertise
Item 2.02: Results of Operations and Financial Condition
- Fiscal Q2 2026 results covered quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains financial results and management commentary
Item EX-99.1: Item EX-99.1
- Q2 sales rose to $0.4M from $0.1M, but $1.2M cost of goods sold reflects a $0.7M inventory reserve and unused capacity costs
- V012 Phase 3 interim results showed 91 additional catheter-free days and infection rates of 6 versus 23 per 100 patient years
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule
- Nasdaq deficiency: HUMA below $1.00 bid-price requirement for 30 consecutive business days
- 180-day cure period through January 27, 2027
AI summaries of HUMA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for HUMA
Don't miss the next HUMA filing
- Alerts as it files. A push when HUMA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut HUMA, by share count.
- Ask anything. An AI agent that reads every HUMA filing and answers with sources.
HUMA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Jones Keith Anthony | Buy | Sep 14, 2026 | 10,000 | $0.56 |
| Jones Keith Anthony | Buy | Aug 20, 2026 | 10,000 | $0.69 |
| Jones Keith Anthony | Buy | Aug 17, 2026 | 30,000 | $0.59 |
| Bamforth John Philip | A | Jun 11, 2026 | 80,000 | - |
| Wallace Max N. | A | Jun 11, 2026 | 80,000 | - |
| Dougan Brady W | A | Jun 11, 2026 | 0 | - |
| Windham-Bannister Susan Richards | A | Jun 11, 2026 | 80,000 | - |
| Constantino Michael T. | A | Jun 11, 2026 | 80,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $0 | $2.0M |
| Operating Income | -$100.0M | -$114.4M | -$108.1M |
| Net Income | -$110.8M | -$148.7M | -$40.8M |
| Op. Margin | - | - | -5306.0% |
| Net Margin | - | - | -2003.6% |
| Balance Sheet | |||
| Total Assets | - | $137.9M | $116.4M |
| Equity | $13.5M | -$52.7M | $3.1M |
| ROE | -817.8% | 282.3% | -1313.4% |
| Per Share | |||
| EPS | - | $-1.26 | $-0.26 |
| Cash Flow | |||
| Operating CF | -$73.3M | -$98.1M | -$105.0M |
| CapEx | - | $1.6M | $884K |
Source: XBRL data in Humacyte, Inc. (HUMA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate HUMA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 24 | $19.3M |
| Q1 2026 | 26 | $17.9M |
| Q4 2025 | 24 | $32.7M |
| Q3 2025 | 26 | $49.9M |
| Q2 2025 | 25 | $67.1M |
| Q1 2025 | 23 | $34.5M |
| Q4 2024 | 17 | $72.9M |
| Q3 2024 | 13 | $48.5M |
- Vanguard Capital Management LLC+2.95M (+41%)
- Millennium Management+1.80M (+1665%)
- AQR Capital Management+672.4K (+35%)
- Bank of America Corp+182.5K (+46%)
- Morgan Stanley+158.4K (+85%)
- BlackRock−7.48M (-61%)
- State Street Corp−2.20M (-72%)
- Vanguard Portfolio Management LLC−849.3K (-60%)
- Northern Trust−767.4K (-63%)
- BNY Mellon−297.6K (-84%)
- Citadel Advisors LLC+1.44M
- T. Rowe Price Group−112.2K
- Prudential Financial−22.2K
- StoneX Group Inc.−16.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 178 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
HUMA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 28, 2026 | - | Analysis | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 8-K | Jul 31, 2026 | - | Analysis | - |
| SC 13G | Jun 22, 2026 | - | - | |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 8-K | Jun 9, 2026 | - | Analysis | |
| 8-K | Jun 5, 2026 | - | Analysis | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 20, 2026 | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
HUMA SEC filings: frequently asked questions
Are HUMA insiders buying or selling?
In the last 90 days, Humacyte, Inc. (HUMA) officers, directors and 10% owners reported 3 open-market purchases worth $30,370 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold HUMA stock?
As of June 30, 2026, the largest Humacyte, Inc. (HUMA) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($7.9 million), BlackRock ($3.8 million), AQR Capital Management ($2.0 million), Millennium Management ($1.5 million), Citadel Advisors LLC ($1.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was HUMA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Humacyte, Inc. (HUMA) reported revenue of $2.0 million and a net loss of $40.8 million. Diluted EPS was -$0.26. The figures come from the XBRL data in the 10-K.
What did HUMA report in its latest 8-K?
Humacyte, Inc. (HUMA) filed an 8-K on September 28, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 5.02 (Departure/Appointment of Directors or Principal Officers). Board appointments of Mr. Coward and Mr. Kuznik, signaling changes in Humacyte’s governance and strategic oversight.
What are the latest HUMA SEC filings?
Humacyte, Inc. (HUMA) filed its latest 10-K annual report on March 27, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on September 28, 2026 and a Form 4 insider filing on September 15, 2026.
What is HUMA's SEC CIK number?
Humacyte, Inc. (HUMA)'s SEC Central Index Key (CIK) is 1818382. EDGAR lists every HUMA filing under that number.
Ask anything about HUMA
The research agent reads HUMA's filings, financials, insider trades and 13F holders, then answers with sources.